Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

First Trust NASDAQ Cybersecurity ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Cybersecurity ETF vs Zimmer Biomet Holdings Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.23, while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc pays a 0.98% dividend while First Trust NASDAQ Cybersecurity ETF pays none, and First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.

CIBRZBH
52-Week High
$100.60$107.71
52-Week Low
$60.74$79.58
Market Cap
$18.65B
Sector
Health
Enterprise Value
$25.72B
Dividend Yield
0.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Cybersecurity ETF

CIBR, the First Trust Nasdaq Cybersecurity ETF, trades at $97.85, up 1.51% on the day, with a bullish technical signal from moving averages. The ETF has shown strong performance, reportedly outperforming the S&P 500 by three to one year-to-date as of June 5, 2026 (24/7 Wall Street). Recent news highlights institutional activity, including Bank of America reducing its stake while First Trust Advisors increased its position.

The outlook for CIBR is positive, driven by growing cybersecurity spending exceeding $300 billion in 2026 and AI-driven demand. Risks include high concentration in tech stocks and market volatility. Analyst sentiment is optimistic, with upgrades citing reasonable valuations and secular growth trends.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.

The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.

Returns comparison

Trailing returns across standard periods

About First Trust NASDAQ Cybersecurity ETF

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.

Read more on CIBR

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH